Area of research
Immunology · Surgery
Research interest
is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments, most recently the Gold Medal of the European Society of Cardiology (2011) and the Basic Research Prize of the American Heart Association (2011). His areas of clinical expertise include general and preventive cardiology. Dr. Libby’s professional memberships include the Association of American Physicians , the American Society for Clinical Investigation , and elected honorary memberships in the British Atherosclerosis Society , the Japan Circulation Society , and the Japanese College of Cardiology . He has served as the President of the Association of University Cardiologists . He also has served in many roles as a volunteer for t
Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial
Echoes of inflammation: cardiovascular risk in giant cell arteritis
Gamut of Patients Referred to Cardiology for Question of Clonal Hematopoiesis
Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure
Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial
The Price of Cardiovascular Risk Reclassification With Lp(a) Testing
Author Correction: The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis
Acute coronary syndromes: mechanisms, challenges, and new opportunities
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement
Carotid artery atherosclerosis: mechanisms of instability and clinical implications
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease
C-reactive protein and cardiovascular risk in the general population
C-reactive protein and cardiovascular risk in the general population
Expanding the triglyceride range in clinical trials: therapeutic opportunities
Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis
Plaque erosion risk and <i>JAK2</i> V617F variant
Plaque erosion risk and <i>JAK2</i> V617F variant
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease
Myocardial infarction, stroke and arterial stenosis: time to reassess a major misunderstanding
Changes in Blood Eosinophil Counts Predict the Death of Patients With Myocardial Infarction After Hospital Discharge
Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long‐Term Cardiovascular Mortality
Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease
Vaccination in patients with heart failure in practice
Direct Interleukin-6 Inhibition Blunts Arterial Thrombosis by Reducing Collagen-Mediated Platelet Activation
Acute coronary syndrome with plaque erosion: clinical characteristics, mechanisms, and unmet needs
Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRE
Eicosapentaenoic acid limits the more rapid oxidation of lipoprotein(a) compared with other apolipoprotein B particles
Human plasma proteomic profile of clonal hematopoiesis